Durable partial response of pulmonary metastases from primary sublingual gland squamous cell carcinoma after pembrolizumab failure: Salvage therapy with paclitaxel plus cetuximab
Open Access
- 21 October 2025
- journal article
- Published by Elsevier in Oral Oncology Reports
- Vol. 16
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neckFrontiers in Oncology, 2023
- Primary squamous cell carcinoma of the parotid gland: clinicopathological characteristics, treatment, and prognosisInternational Journal of Oral and Maxillofacial Surgery, 2021
- Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent ExocytosisCancer Immunology Research, 2020
- Immunotherapy for head and neck cancer: Recent advances and future directionsOral Oncology, 2019
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Oncologic outcome and potential prognostic factors in primary squamous cell carcinoma of the parotid glandBMC Cancer, 2019
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016